CVM - CEL-SCI Corporation
CEL-SCI Corporation
8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703 506 9460
https://cel-sci.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Geert R. Kersten Esq. | Chief Exec. & Financial Officer, Treasurer and Director | 681.99k | N/A | 1959 |
| Ms. Patricia B. Prichep | Sr. VP of Operations & Corp. Sec. | 286.03k | N/A | 1951 |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer | 340.59k | N/A | 1956 |
| Dr. Daniel H. Zimmerman Ph.D. | Sr. VP of Research & Cellular Immunology | 262.86k | N/A | 1941 |
| Mr. John Cipriano | Sr. VP of Regulatory Affairs | 239.1k | N/A | 1942 |
Description
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Corporate governance
CEL-SCI Corporation’s ISS governance QualityScore as of 1 May 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 6; Compensation: 10.
